Forty Seven Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
-- Updated Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab in Relapsed/Refractory Non-Hodgkin’s Lymphoma (r/r
-- Updated Data from Phase 1b Trial of 5F9 as a Monotherapy and in Combination with Azacitidine in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Expected in Second Quarter of 2019 –
-- Expanded Discovery-Stage Pipeline with FSI-174, an Anti-cKIT Antibody –
-- Management to Host Conference Call at
“Our ultimate goal at Forty Seven is to enable more patients to defeat their cancers by delivering a new class of therapies, which take advantage of the innate immune system as a powerful therapeutic target,” said
Dr. McCamish continued, “As we move into 2019, we are building on this forward momentum, with a particular focus on executing our clinical plans. We expect to generate meaningful data across multiple programs this year, beginning with updated clinical data from our Phase 1b/2 trial of 5F9 plus rituximab in r/r
Fourth Quarter and Recent Business Highlights:
January 2019, Forty Seven announced FSI-174, an anti-cKIT antibody, as its third development candidate. Forty Seven plans to develop FSI-174 in combination with anti-CD47 antibodies as a non-toxic transplant conditioning regimen, as well as a treatment for targeted hematologic malignancies.
December 2018, Forty Seven presented preclinical data at the 60th American Society of Hematology(ASH) Annual Meeting, providing additional mechanistic insight into why its proprietary 5F9 priming and maintenance dosing strategy mitigates the on-target anemia caused by the clearance of aged red blood cells (RBCs). The data show that the initial priming dose of 5F9 results in a near complete loss of CD47 on surviving, younger RBCs, making these cells less susceptible to phagocytosis and decreasing the risk of CD47 antibody-induced anemia during subsequent maintenance dosing.
- Also at ASH, Forty Seven presented new preclinical data supporting the development of 5F9 and azacitidine for the treatment of AML. The data show that the combination of 5F9 and azacitidine increases the phagocytic elimination of AML blast cells by human macrophages in vitro, enhances clearance of AML in vivo, and prolongs survival compared to single-agent treatment with either 5F9 or azacitidine alone.
November 2018, Forty Seven announced that proof-of-concept data from the Phase 1b portion of its Phase 1b/2 clinical trial evaluating 5F9 in combination with rituximab in patients with r/r NHL were published in the New England Journal of Medicine.
Key Upcoming Milestones:
The company expects to achieve the following milestones by the end of 2019:
- Report data from the Phase 1b/2 trial of 5F9 in combination with rituximab in patients with r/r
NHL, including safety, efficacy and duration of response across various dosing cohorts, in the second quarter.
- Report data from the Phase 1b trial of 5F9 as a monotherapy and in combination with azacitidine in patients with AML and MDS, including safety and initial efficacy data, in the second quarter.
- Report data from the Phase 1b trial of 5F9 in combination with avelumab in patients with ovarian cancer in the fourth quarter.
- Report data from the Phase 1b trial of 5F9 in combination with cetuximab in patients with colorectal cancer in the fourth quarter.
- Report preclinical data and complete IND-enabling studies for FSI-174 in the second half.
- Completing IND-enabling studies for FSI-189 in the second half.
Fourth Quarter and Full Year 2018 Financial Results:
- Cash Position: As of
December 31, 2018, cash, cash equivalents and short-term investments were $139.0 million, as compared to $88.1 millionas of December 31, 2017. This increase reflects net proceeds of $116.3 millionfrom Forty Seven’s initial public offering of common stock, which closed in July 2018. The company expects that its cash, cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements through the first half of 2020.
- R&D Expenses: R&D expenses were
$13.9 millionfor the fourth quarter of 2018 and $56.7 millionfor the full year ended December 31, 2018, as compared to $10.0 millionfor the fourth quarter of 2017 and $37.2 millionfor the full year ended December 31, 2017. This increase was primarily due to an increase in third party costs associated with the continued advancement of the company’s clinical development efforts, an increase in personnel-related costs, including stock-based compensation, and non-recurring upfront payments of $8.8 millionassociated with two licensing deals. This increase was partially offset by $5.3 millionin grant funding and cost sharing from the California Institute of Regenerative Medicine, the Leukemia and Lymphoma Society, and Merck KGaA.
- G&A Expenses: G&A expenses were
$3.8 millionfor the fourth quarter of 2018 and $15.4 millionfor the full year ended December 31, 2018, as compared to $2.6 millionfor the fourth quarter of 2017 and $8.1 millionfor the full year ended December 31, 2017. This increase was primarily due to an increase in personnel-related costs and expenses incurred in connection with operating as a public company.
- Net Loss: Net loss was
$17.2 millionfor the fourth quarter of 2018 and $70.4 millionfor the full year ended December 31, 2018, or a net loss per share of $0.56and $3.75, respectively, as compared to $12.3 millionfor the fourth quarter of 2017 and $44.9 millionfor the full year ended December 31, 2017, or a net loss per share of $1.88and $6.94, respectively.
Conference Call Information:
Forty Seven will host a live conference call and webcast at 4:30 p.m. ET today to discuss fourth quarter and full year 2018 financial results and recent business activities. The conference call may be accessed by (866) 953-0780 (domestic) or (630) 652-5854 (international) and referring to conference ID 1089506. A webcast of the conference call will be available in the Investors section of the Forty Seven website at https://ir.fortyseveninc.com. The archived webcast will be available on Forty Seven’s website approximately two hours after the conference call and will be available for 30 days following the call.
Forward Looking Statements:
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the timing of and outcome of results from the Phase 1b/2 trial of 5F9 in combination with rituximab in patients with r/r
For journalist inquiries, please contact
For investor inquiries, please contact
Statement of Operations Data
(In thousands, except share and per share data)
|Three Months Ended
|Research and development||$||13,940||$||9,962||$||56,673||$||37,174|
|General and administrative||3,844||2,621||15,432||8,130|
|Total operating expenses||17,784||12,583||72,105||45,304|
|Loss from operations||(17,784||)||(12,583||)||(72,105||)||(45,304||)|
|Interest and other income, net||570||253||1,735||406|
|Net loss per share, basic and diluted||$||(0.56||)||$||(1.88||)||$||(3.75||)||$||(6.94||)|
|Shares used in computing net loss per share, basic and diluted||31,010,898||6,559,128||18,768,868||6,468,634|
Selected Balance Sheet Data
|As of December 31, 2018||As of December 31, 2017|
|Cash, cash equivalents and short-term investments||$||139,023||$||88,111|
|Total stockholders’ equity||133,221||83,462|
Source: Forty Seven, Inc.